Strattice与SurgiMend在脱细胞真皮基质辅助即刻假体乳房再造中的比较
这项回顾性研究在3家医院比较了猪源性Strattice与牛源性SurgiMend在即刻假体乳房再造中的临床结局,共82例患者行97侧再造。Strattice组假体丢失率20%高于SurgiMend组7%但未达统计学显著(p=0.077),而脱细胞真皮基质丢失率和再手术率显著更高,SurgiMend组红乳发生率显著更高。
要点
- Strattice组脱细胞真皮基质丢失率14%显著高于SurgiMend组0%(p=0.014)。
- Strattice组再手术率33%显著高于SurgiMend组7%(p=0.002)。
- SurgiMend组红乳发生率21%显著高于Strattice组6%(p=0.022)。
核心结论
- 在即刻假体乳房再造中,使用SurgiMend的临床结局(包括假体丢失、脱细胞真皮基质丢失和再手术率)显著优于Strattice。
- 作者认为需要一项样本量适当的随机试验来提供进一步信息。
研究设计与样本
- 回顾性研究,在3家医院开展,纳入所有使用Strattice或SurgiMend行即刻假体乳房再造的患者。
- 共82例患者(Strattice组45例,SurgiMend组37例),行97侧即刻假体乳房再造(Strattice组54侧,SurgiMend组43侧)。
主要发现
- 主要结局假体丢失率:Strattice组20%(n=10)vs SurgiMend组7%(n=3),卡方检验p=0.077,未达统计学显著。
- 脱细胞真皮基质丢失率:Strattice组14%(n=7)vs SurgiMend组0%,Fisher精确检验p=0.014,Strattice组显著更高。
- 再手术率:Strattice组33%(n=17)vs SurgiMend组7%(n=3),卡方检验p=0.002,Strattice组显著更高。
- 红乳发生率:SurgiMend组21%(n=9)vs Strattice组6%(n=3),卡方检验p=0.022,SurgiMend组显著更高。
- 血清肿、伤口问题和感染率两组相似;两组年龄、合并症、标本重量和假体体积无差异;Strattice组全部使用引流,SurgiMend组36例(84%)使用引流。
局限性
- 原文在结论中提出需要一项样本量适当的随机试验来提供进一步信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Strattice (porcine derivative) and SurgiMend (bovine derivative) are the two most common acellular dermal matrices used in breast reconstruction in the United Kingdom. This retrospective study compared clinical outcomes in immediate implant-based breast reconstruction patients. METHODS: The study, conducted across three hospitals, included all patients who underwent immediate implant-based breast reconstruction using Strattice and SurgiMend. The primary outcome measure was implant loss rate. Secondary outcome measures included acellular dermal matrix loss rate, seroma formation, and minor and major complication rates. Intergroup comparison was performed. RESULTS: Eighty-two patients (Strattice, n = 45; SurgiMend, n = 37) underwent 97 immediate implant-based breast reconstructions (Strattice, n = 54; SurgiMend, n = 43). There were no differences between groups for age, comorbidities, specimen weight, or implant volume. Drains were used in all Strattice and 36 (84 percent) SurgiMend cases. The implant loss rate was higher for Strattice (n = 10, 20 percent) compared with SurgiMend (n = 3, 7 percent) but failed to reach statistical significance (chi-square test, p = 0.077). The acellular dermal matrix loss rate was significantly higher (Fisher's exact test, p = 0.014) in the Strattice group (n = 7, 14 percent), with no acellular dermal matrix loss with SurgiMend. The reoperation rate was also significantly higher (chi-square test, p = 0.002) in the Strattice group (n = 17, 33 percent, versus n = 3, 7 percent). The incidence of red breast was significantly higher (chi-square test, p = 0.022) in the SurgiMend group (n = 9, 21 percent, versus n = 3, 6 percent). Seroma, wound problems, and infection rates were similar. CONCLUSIONS: Clinical outcomes, including implant loss, acellular dermal matrix loss, and reoperation rates, are significantly better when using SurgiMend in immediate implant-based breast reconstruction compared with Strattice. An appropriately powered randomized trial is needed to provide further information. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Mazari FAK, Wattoo GM, Kazzazi NH, et al. The Comparison of Strattice and SurgiMend in Acellular Dermal Matrix-Assisted, Implant-Based Immediate Breast Reconstruction. Plast Reconstr Surg. 2018. PMID: 29369979. doi:10.1097/PRS.0000000000004018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。